Literature DB >> 17276744

FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Seiji Fukumoto1, Takeyoshi Yamashita.   

Abstract

FGF23 was identified as the last member of FGF23 family. Recent investigations indicate that excess actions of FGF23 cause several hypophosphatemic diseases whereas deficient FGF23 activity results in hyperphosphatemic tumoral calcinosis. These results indicate that FGF23 is a hormone that regulates serum phosphate level in contrast to other FGF family members that work as local factors. Furthermore, FGF23 requires Klotho for its signaling in addition to a canonical FGF receptor. These unique characteristics of FGF23 expanded our knowledge about the diversity of FGF family members and specificity of FGF23.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17276744     DOI： 10.1016/j.bone.2006.12.062

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


  52 in total

1.  Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis.

Authors:  Atsushi Sugita; Shinji Kawai; Tetsuyuki Hayashibara; Atsuo Amano; Takashi Ooshima; Toshimi Michigami; Hideki Yoshikawa; Toshiyuki Yoneda
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

2.  Hypophosphataemia-inducing mesenchymal tumour in the foot.

Authors:  Christa Bauer; Rolf Brücker; Stefan Bützberger; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2010-10-06

Review 3.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

4.  FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Steven Vonderfecht; Jennifer Weiszmann; Randy Hecht; Jamila Gupte; Todd Hager; Zhulun Wang; Richard Lindberg; Yang Li
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

Review 5.  [Metabolic bone disease osteomalacia].

Authors:  M A Reuss-Borst
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

6.  Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.

Authors:  Catherine A Brownstein; Junhui Zhang; Althea Stillman; Bruce Ellis; Nancy Troiano; Douglas J Adams; Caren M Gundberg; Richard P Lifton; Thomas O Carpenter
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

Review 7.  Nonclassic actions of vitamin D.

Authors:  Daniel Bikle
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

8.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Authors:  Rodrigo B Oliveira; Ana L E Cancela; Fabiana G Graciolli; Luciene M Dos Reis; Sérgio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Vanda Jorgetti; Maria E Canziani; Rosa M A Moysés
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

9.  Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.

Authors:  Leo Joseph; Sandra N Hing; Nadege Presneau; Paul O'Donnell; Tim Diss; Bernadine D Idowu; Selvanayagam Joseph; Adrienne Margaret Flanagan; David Delaney
Journal:  Skeletal Radiol       Date:  2009-10-15       Impact factor: 2.199

10.  Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis.

Authors:  Clemens Bergwitz; Santanu Banerjee; Hilal Abu-Zahra; Hiroshi Kaji; Akimitsu Miyauchi; Toshitsugu Sugimoto; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.